149 related articles for article (PubMed ID: 16964833)
1. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
Durante-Mangoni E; Iardino P; Utili R; Adinolfi LE; Ruggiero G
Antivir Ther; 2006; 11(5):637-40. PubMed ID: 16964833
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
[TBL] [Abstract][Full Text] [Related]
4. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis.
Giorgini A; Capsoni F; Podda M; Lleó A; Battezzati PM; Ongari AM; Selmi C; Benetti A; Malinverno F; Rossaro L; Gershwin ME; Zuin M
Ann N Y Acad Sci; 2009 Sep; 1173():847-57. PubMed ID: 19758237
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
Koskinas J; Zacharakis G; Sidiropoulos J; Elefsiniotis J; Savvas S; Kotsiou S; Kountouras D; Schina M; Kostopoulos P; Archimandritis A
J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
Liu YL; Du XF; Chen XY; Ma LN; Guo DD; Lu JF; Cao ZH; Zhang YH
Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
[TBL] [Abstract][Full Text] [Related]
7. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
[TBL] [Abstract][Full Text] [Related]
8. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Mac Nicholas R; Norris S
Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
[TBL] [Abstract][Full Text] [Related]
9. [Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
Porubcin S; Schréter I; Kristian P; Pellová A
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):74-8. PubMed ID: 18756437
[TBL] [Abstract][Full Text] [Related]
10. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients.
Fukuda A; Kobayashi H; Teramura K; Yoshimoto S; Ohsawa N
Cytokines Cell Mol Ther; 2000 Sep; 6(3):149-54. PubMed ID: 11140884
[TBL] [Abstract][Full Text] [Related]
11. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
Lebray P; Nalpas B; Vallet-Pichard A; Broissand C; Sobesky R; Serpaggi J; Fontaine H; Pol S
Antivir Ther; 2005; 10(6):769-76. PubMed ID: 16218177
[TBL] [Abstract][Full Text] [Related]
12. Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
Tarantino L; De Rosa A; Tambaro O; Ripa C; Celiento M; Schiano A
Infez Med; 2009 Mar; 17(1):20-3. PubMed ID: 19359820
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
Tandon P; Doucette K; Fassbender K; Vandermeer B; Durec T; Dryden DM
J Viral Hepat; 2011 Jul; 18(7):e381-93. PubMed ID: 21692951
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
Saleh MI; Hindi NN
Naunyn Schmiedebergs Arch Pharmacol; 2018 Sep; 391(9):953-963. PubMed ID: 29872876
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
Iacobellis A; Cozzolongo R; Minerva N; Valvano MR; Niro GA; Fontana R; Palmieri O; Ippolito A; Andriulli A
Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
[TBL] [Abstract][Full Text] [Related]
16. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence.
Lodato F; Azzaroli F; Tamè MR; Di Girolamo M; Buonfiglioli F; Mazzella N; Cecinato P; Roda E; Mazzella G
World J Gastroenterol; 2009 Nov; 15(43):5449-54. PubMed ID: 19916175
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C.
Iio E; Matsuura K; Nishida N; Maekawa S; Enomoto N; Nakagawa M; Sakamoto N; Yatsuhashi H; Kurosaki M; Izumi N; Hiasa Y; Masaki N; Ide T; Hino K; Tamori A; Honda M; Kaneko S; Mochida S; Nomura H; Nishiguchi S; Okuse C; Itoh Y; Yoshiji H; Sakaida I; Yamamoto K; Watanabe H; Hige S; Matsumoto A; Tanaka E; Tokunaga K; Tanaka Y
Hum Genet; 2015 Mar; 134(3):279-89. PubMed ID: 25515861
[TBL] [Abstract][Full Text] [Related]
18. Treatment induced leucopenia in hepatitis C and Role of G-CSF in its management.
Shafi MS; Sheikh NI; Rizvi F; Afzal M; Manzoor S
J Coll Physicians Surg Pak; 2009 Jun; 19(6):346-9. PubMed ID: 19486571
[TBL] [Abstract][Full Text] [Related]
19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
20. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
